Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.

Advances in analytical methods, imaging techniques and an increased understanding of the influence of pharmacogenetic factors have added to our knowledge of the pharmacology of many chemotherapeutic agents. Extending the use of these approaches to pharmacodynamic end-points, together with the application of population-based modelling techniques, offers the potential to develop truly individualized therapy in the future.

[1]  M. Karlsson,et al.  Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy , 2006, Cancer Chemotherapy and Pharmacology.

[2]  B. Cheson,et al.  Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.

[3]  A. Heerschap,et al.  Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy. , 2005, Critical reviews in oncology/hematology.

[4]  S. Madhusudan,et al.  The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. , 2005, Cancer treatment reviews.

[5]  Sharon Marsh,et al.  Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel , 2005, Clinical Cancer Research.

[6]  S. Guichard,et al.  Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  O. Colvin,et al.  Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Rebbeck,et al.  Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. , 2005, Journal of Clinical Oncology.

[9]  A. Boddy,et al.  Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study , 2005, Clinical Cancer Research.

[10]  Steven Mennerick,et al.  An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Joanne Wang,et al.  A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  T. Yamauchi,et al.  A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells. , 2005, Biochemical pharmacology.

[13]  David A Jones,et al.  Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Geoghegan,et al.  Biochemical applications of mass spectrometry in pharmaceutical drug discovery. , 2005, Mass spectrometry reviews.

[15]  Walter Kolch,et al.  The molecular make-up of a tumour: proteomics in cancer research. , 2005, Clinical science.

[16]  T. Rebbeck,et al.  Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. , 2005, Cancer research.

[17]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[18]  Mats O Karlsson,et al.  Pharmacokinetic/pharmacodynamic modelling in oncological drug development. , 2005, Basic & clinical pharmacology & toxicology.

[19]  A. Jakobsen,et al.  Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Sloan,et al.  Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Meropol,et al.  UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Andrew N Lane,et al.  The promise of metabolomics in cancer molecular therapeutics. , 2004, Current opinion in molecular therapeutics.

[23]  P. Vicini,et al.  Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors , 2004, Clinical Cancer Research.

[24]  E. Esteban,et al.  Phase I clinical trial of fixed–dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation , 2004, Cancer.

[25]  Ping Guo,et al.  Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[26]  E. Gamelin,et al.  Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity , 2004, Clinical Cancer Research.

[27]  Paolo Magni,et al.  Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.

[28]  W. Kamps,et al.  Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic Leukemia , 2003, Clinical pharmacology and therapeutics.

[29]  Sharon Marsh,et al.  Irinotecan pathway genotype analysis to predict pharmacokinetics. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  David Z. D'Argenio,et al.  Physiologically-Based Pharmacokinetics and Molecular Pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and Its Active Metabolite in Tumor-Bearing Mice , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[31]  J. Verweij,et al.  Distribution of paclitaxel in plasma and cerebrospinal fluid , 2003, Anti-Cancer Drugs.

[32]  S. Osman,et al.  Metabolic activation of temozolomide measured in vivo using positron emission tomography. , 2003, Cancer research.

[33]  Roger N Gunn,et al.  2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. , 2003, Journal of the National Cancer Institute.

[34]  Danny Rischin,et al.  Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Mark J Ratain,et al.  Population pharmacokinetic model for irinotecan and two of its metabolites, SN‐38 and SN‐38 glucuronide , 2002, Clinical pharmacology and therapeutics.

[37]  I. Blair,et al.  Analysis of anticancer drugs and their metabolites by mass spectrometry. , 2002, Current drug metabolism.

[38]  B. Goh,et al.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Blesch,et al.  Population Pharmacokinetic Analysis of the Major Metabolites of Capecitabine , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[40]  D. Roberts,et al.  A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine)platinum(II) in human plasma ultrafiltrate. , 2002, Analytical chemistry.

[41]  C. Felix,et al.  Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. , 2001, Journal of mass spectrometry : JMS.

[42]  S. Osman,et al.  Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. , 2001, Cancer research.

[43]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[44]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[45]  S. Osman,et al.  Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action , 2000, The Lancet.

[46]  N. Cross,et al.  Detection and quantification of residual disease in chronic myelogenous leukemia , 2000, Leukemia.

[47]  S. Rodenhuis,et al.  HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF THE STABILIZED CYCLOPHOSPHAMIDE METABOLITE 4-HYDROXYCYCLOPHOSPHAMIDE IN PLASMA AND RED BLOOD CELLS , 2000 .

[48]  W. Howald,et al.  Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[49]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  G. Peters,et al.  Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  S. Osman,et al.  Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Souhami,et al.  Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  B. Reigner,et al.  Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Relling,et al.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[55]  M. Relling,et al.  Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. , 1996, Pharmacogenetics.

[56]  P. Ellis,et al.  Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  E. Gelpí.  Biomedical and biochemical applications of liquid chromatography-mass spectrometry. , 1995, Journal of chromatography. A.

[58]  J. Radich,et al.  Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. , 1994, Leukemia.

[59]  C. Presant,et al.  Association of intratumoral pharmacokinetics of fluorouracil with clinical response , 1994, The Lancet.

[60]  J. Griffiths,et al.  Tumour pharmacokinetics?—we do need to know , 1994, The Lancet.

[61]  V. R. McCready,et al.  The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-α using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: A pilot study , 1993 .

[62]  J. Lilleyman,et al.  Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? , 1993, BMJ.

[63]  F. Oesch,et al.  DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. , 1992, Cancer research.

[64]  P. Langenberg,et al.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  G. Houin,et al.  Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children. , 1991, Journal of pharmaceutical sciences.

[66]  S. Steinberg,et al.  Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. , 1990, Cancer research.

[67]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Scott M Turner,et al.  Emerging applications of kinetic biomarkers in preclinical and clinical drug development. , 2005, Current opinion in drug discovery & development.

[69]  Christian Piepenbrock,et al.  Identifying DNA Methylation Biomarkers of Cancer Drug Response , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[70]  J. Steimer,et al.  A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients , 2004, Cancer Chemotherapy and Pharmacology.

[71]  M. Tilby,et al.  Measurement of covalent drug-DNA interactions at the nucleotide level in cells at pharmacologically relevant doses. , 2001, Methods in enzymology.

[72]  A. Boddy,et al.  Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. , 1997, British Journal of Cancer.

[73]  V. Gilard,et al.  Urinary stability of carboxycyclophosphamide and carboxyifosfamide, two major metabolites of the anticancer drugs cyclophosphamide and ifosfamide , 1997, Cancer Chemotherapy and Pharmacology.

[74]  G. Bonadonna,et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  R. Diasio,et al.  Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. , 1988, The Journal of clinical investigation.